Endogenous / BiologyEndogenousHuman-supportedUpdated 2026-04-24

Peptide reference file

TRH

Trending #39 in Endogenous2.1k searches/moProven

TRH is a hypothalamic releasing peptide that regulates TSH and prolactin-related pituitary signaling.

Current readout: human-supported evidence, endogenous status, endogenous approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 638678 | 17953 PubMed results | 21 trial records | 1 DailyMed label | 1 Drugs@FDA application

TRH is mostly discussed because it matters as one of the classic releasing hormones that shaped endocrine peptide medicine.

The public claim is straightforward: It matters as one of the classic releasing hormones that shaped endocrine peptide medicine. Foundational endocrine peptide biology with diagnostic and historical drug relevance.

In plain language, tRH is a hypothalamic releasing peptide that regulates TSH and prolactin-related pituitary signaling.

Human-supportedEndogenous
Hypothalamic peptideThyroid axisPituitary signaling

Aliases: Thyrotropin-releasing hormone, Protirelin

SpecimenTRH specimen
CCCCCHHHHHHHNNO
Formula
C16H22N6O4
Mass
362.38
Evidence
Human-supported
Elements
4

Most commonly discussed in relation to Hypothalamic peptide, Thyroid axis, Pituitary signaling.

What TRH is

TRH is a hypothalamic releasing peptide that regulates TSH and prolactin-related pituitary signaling.

TRH is grouped under Endogenous / Biology / Approved / Clinical on PeptideFactCheck because it matters as one of the classic releasing hormones that shaped endocrine peptide medicine.

The useful starting point is to separate the molecule itself from the internet story around it. It matters as one of the classic releasing hormones that shaped endocrine peptide medicine.

Why people keep looking it up

It matters as one of the classic releasing hormones that shaped endocrine peptide medicine.

TRH is a hypothalamic releasing peptide that regulates TSH and prolactin-related pituitary signaling.

TRH tends to stay in the conversation because it touches a familiar public theme: hypothalamic peptide, thyroid axis, and pituitary signaling. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Foundational endocrine peptide biology with diagnostic and historical drug relevance.

Human endocrine biology is well established.

Mechanistic support around thyroid-axis control is extensive.

Why this page carries the current tier: Foundational endocrine peptide biology with diagnostic and historical drug relevance.

The current seed trail for TRH is pulling from 2 databases sources and 1 literature source.

Safety, limits, and regulatory context

This is a reference endocrinology entry, not a broad self-optimization peptide category.

TRH is tracked here as endogenous biology.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for TRH. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for TRH is CID 638678. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
638678
Formula
C16H22N6O4
Molecular weight
362.38
InChIKey
XNSAINXGIQZQOO-SRVKXCTJSA-N

Matched synonyms include protirelin, 24305-27-9, Thyroliberin, Lopremone, Synthetic TRH, Rifathyroin, Thypinone, Thyrotropin-releasing factor.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for TRH returns 21 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for TRH returns 17953 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Label and regulatory records

For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.